Skip to search formSkip to main contentSkip to account menu

vorapaxar

Known as: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

LactonesPlatelet Aggregation InhibitorsPyridines

Narrower (2)

SCH-530348vorapaxar sulfate
vorapaxar 2.08 MG Oral Tablet [Zontivity]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior… 
2017
2017
Benefit‐Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments
Review
2016
Review
2016
Developing drugs for use before, during and soon after percutaneous coronary intervention
ABSTRACT Introduction: Percutaneous coronary intervention (PCI) is a milestone for treating coronary artery disease (CAD… 
Review
2015
Review
2015
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
The optimal utilization of antiplatelet therapy in patients with renal impairment (RI) following acute coronary syndromes (ACS… 
Review
2013
Review
2013
Low-dose anticoagulation for secondary prevention in acute coronary syndrome.
2012
2012
Vorapaxar expands antiplatelet options
Summary Vorapaxar is the first substance of a new class of antiplatelet drugs that has been tested in large clinical trials. The… 
2012
2012
Atopaxar. A novel player in antiplatelet therapy?
Atopaxar, also known as E 5555 is a novel reversible protease-activated receptor-1 (PAR-1) thrombin receptor antagonist. To date… 
2010
2010
SCH 602539, a Protease-Activated Receptor-1 Antagonist, Inhibits Thrombosis Alone and in Combination With Cangrelor in a Folts Model of Arterial Thrombosis in Cynomolgus Monkeys
Objective—To determine the antithrombotic effects of SCH 602539, an analog of the selective protease-activated receptor (PAR)-1… 
2010
2010
Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
1991
1991
Platelet aggregation inhibitors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)